2016
DOI: 10.1002/14651858.cd011991.pub2
|View full text |Cite
|
Sign up to set email alerts
|

Short-course oral steroids alone for chronic rhinosinusitis

Abstract: At the end of the treatment course (two to three weeks) there is an improvement in health-related quality of life and symptom severity in patients with chronic rhinosinusitis with nasal polyps taking oral corticosteroids compared with placebo or no treatment. The quality of the evidence supporting this finding is low. At three to six months after the end of the oral steroid treatment period, there is little or no improvement in health-related quality of life or symptom severity for patients taking an initial c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
88
0
8

Year Published

2016
2016
2019
2019

Publication Types

Select...
10

Relationship

4
6

Authors

Journals

citations
Cited by 106 publications
(96 citation statements)
references
References 63 publications
0
88
0
8
Order By: Relevance
“…Short courses of oral corticosteroids are widely used, and may result in insomnia, mood and gastrointestinal disturbances (84) .…”
Section: Minimising Risks Of Treatmentmentioning
confidence: 99%
“…Short courses of oral corticosteroids are widely used, and may result in insomnia, mood and gastrointestinal disturbances (84) .…”
Section: Minimising Risks Of Treatmentmentioning
confidence: 99%
“…3742 Short courses of systemic steroids have also been well studied in CRSwNP showing improvements in polyp size, symptoms and outcomes. 4345 There is no high level evidence supporting the use of systemic steroids in CRSsNP although they are likely to be effective in the subset of patients who have elevated type 2 inflammation. 46 Despite almost universal prescription for CRS care, strong evidence for the efficacy of antibiotics is still lacking.…”
Section: Conventional Crs and Ar Treatmentmentioning
confidence: 99%
“…инГКС хорошо изучены по всем вышеперечислен-ным показаниям в РКИ и их метаанализах [8,[41][42][43][44][45][46][47][48][49]. При остром, рецидивирующем и хроническом РС доказана эффективность применения инГКС как в виде монотера-пии, так и в качестве дополнения к антибиотикам [11,13].…”
Section: место интраназальных глюкокортикостероидов (ингкс) в терапииunclassified